Raphael Pharmaceutical (RAPH) Cash & Equivalents (2020 - 2025)
Raphael Pharmaceutical (RAPH) reported Cash & Equivalents of $45000.0 for Q4 2025, up 136.84% on a YoY basis from $19000.0 in Q4 2024, and up 1400.0% sequentially from $3000.0 in Q3 2025.
Raphael Pharmaceutical (RAPH) Cash & Equivalents (2020 - 2025) Analysis & Trends
Raphael Pharmaceutical (RAPH) has 6 years of Cash & Equivalents data on file, last reported at $45000.0 in Q4 2025.
- For the quarter ending Q4 2025, Cash & Equivalents rose 136.84% year-over-year to $45000.0; the trailing twelve-month figure through Dec 2025 stood at $45000.0 (up 136.84% YoY), and the FY2025 full-year result was $45000.0, up 136.84% from the prior year.
- Cash & Equivalents advanced to $45000.0 in Q4 2025, from $3000.0 in the prior quarter.
- In the past five years, Cash & Equivalents ranged from a high of $299000.0 in Q3 2023 to a low of $3000.0 in Q3 2025.
- A 5-year average of $113833.3 and a median of $87000.0 in 2022 frame the typical range for Cash & Equivalents.
- Across the five-year window, Cash & Equivalents jumped 655.26% in 2024 and plunged 92.5% in 2025, its largest moves.
- Tracing RAPH's Cash & Equivalents over 5 years: stood at $153000.0 in 2021, then jumped by 88.24% to $288000.0 in 2022, then fell by 20.14% to $230000.0 in 2023, then tumbled by 91.74% to $19000.0 in 2024, then surged by 136.84% to $45000.0 in 2025.
- Business Quant data shows RAPH's Cash & Equivalents at $45000.0 in Q4 2025, $3000.0 in Q3 2025, and $20000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 1.76 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 3.74 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 1.94 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 3.79 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 1.28 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 33.59 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 1.80 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 266.50 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 428.00 Mn |
| 10 | Raphael Pharmaceutical | 27.37 Mn | 27.33 Mn | - | 45,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 45,000.00 |
| Sep 30, 2025 | 3,000.00 |
| Jun 30, 2025 | 20,000.00 |
| Mar 31, 2025 | 50,000.00 |
| Dec 31, 2024 | 19,000.00 |
| Sep 30, 2024 | 40,000.00 |
| Jun 30, 2024 | 120,000.00 |
| Mar 31, 2024 | 287,000.00 |
| Dec 31, 2023 | 230,000.00 |
| Sep 30, 2023 | 299,000.00 |
| Jun 30, 2023 | 111,000.00 |
| Mar 31, 2023 | 38,000.00 |
| Dec 31, 2022 | 288,000.00 |
| Sep 30, 2022 | 93,000.00 |
| Jun 30, 2022 | 135,000.00 |
| Mar 31, 2022 | 81,000.00 |
| Dec 31, 2021 | 153,000.00 |
| Sep 30, 2021 | 37,000.00 |
| Dec 31, 2020 | 95,000.00 |